UCB: Will Cimzia Be Enough?

Cimzia's success is critical for UCB--not least to justify its $2.7 billion Celltech acquisition. But Cimzia will also be a test-case for whether mid-cap pharma can compete in biologics, particularly as the new Medicare program rolls out.